Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection.

Simon, Hans-Uwe; Karaulov, Alexander V; Bachmann, Martin F. (2020). Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection. International archives of allergy and immunology, 181(8), pp. 624-628. Karger 10.1159/000509368

[img] Text
Simon_Strategies to prevent SARS-CoV-2-Mediated.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (464kB) | Request a copy
[img] Text
COVID-19_review_HUS2_Manuskript.pdf - Accepted Version
Restricted to registered users only until 1 September 2021.
Available under License Publisher holds Copyright.

Download (522kB) | Request a copy
[img] Text
Manuskript.pdf - Accepted Version
Restricted to registered users only until 1 September 2021.
Available under License Publisher holds Copyright.

Download (222kB) | Request a copy

A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophil-associated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Hans-Uwe and Bachmann, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1018-2438

Publisher:

Karger

Language:

English

Submitter:

Celine Joray

Date Deposited:

29 Jun 2020 14:53

Last Modified:

15 Sep 2020 16:03

Publisher DOI:

10.1159/000509368

PubMed ID:

32544911

Uncontrolled Keywords:

COVID-19 Eosinophil Immunity Immunopathology SARS-CoV-2 Vaccination

BORIS DOI:

10.7892/boris.144914

URI:

https://boris.unibe.ch/id/eprint/144914

Actions (login required)

Edit item Edit item
Provide Feedback